{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:55:33Z","timestamp":1787003733191,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kyowa Kirin Co., ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Patients undergoing hemodialysis often require numerous medications because of comorbidities including hyperphosphatemia, diabetes, and anemia, coupled with water restrictions. Reducing pill burden may alleviate psychological stress and improve quality of life (QOL). However, standardized instruments such as the EuroQOL 5 Dimensions inadequately measure these effects. We investigated the impact of pill burden on utility scores using a vignette-based time trade-off (TTO) method. Members of the general population were interviewed in person using vignettes representing seven health states with varying daily pill burdens (2, 3, 6, 9, 12, 24, and 36 tablets) in the context of hemodialysis patients, including disease characteristics, symptoms, and daily life restriction. Utility scores were evaluated using the TTO method and the impact of pill burden on QOL was estimated. The mean age (44.5 years) and sex distribution (50.5% male) of the 107 participants closely matched the general population of Japan. Utility scores decreased with higher pill burdens, ranging from 0.373 (0.579) [mean (standard deviation)] for 2 tablets\/day to 0.239 (0.568) for 36 tablets\/day. Compared with 2 tablets\/day, the utility score for 6 tablets\/day was significantly lower [mean (standard deviation) difference: 0.046 (0.223),\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.034, paired t-test)], with the difference showing a more significant as the number of tablets increased. Subgroup analyses by sex and age showed consistent trends with no significant differences between groups. A higher pill burden was associated with lower utility scores, highlighting its negative impact on QOL in patients undergoing hemodialysis. Reducing pill burden may improve QOL and address challenges related to water restrictions.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-19346-3","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:39:15Z","timestamp":1760017155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Estimating the impact of pill burden on health utilities in hemodialysis therapy"],"prefix":"10.1038","volume":"15","author":[{"given":"Hiroo","family":"Shimoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatomo","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ataru","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Hanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"19346_CR1","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.kint.2019.07.012","volume":"96","author":"KJ Jager","year":"2019","unstructured":"Jager, K. J. et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 96, 1048\u20131050 (2019).","journal-title":"Kidney Int."},{"key":"19346_CR2","unstructured":"World Health Organization. The top 10 causes of death. (2024). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death"},{"key":"19346_CR3","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","volume":"388","author":"GBD 2015 Mortality and Causes of Death Collaborators","year":"2016","unstructured":"GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and National life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the global burden of disease study 2015. Lancet 388, 1459\u20131544 (2016).","journal-title":"Lancet"},{"key":"19346_CR4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","volume":"20","author":"A Francis","year":"2024","unstructured":"Francis, A. et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat. Rev. Nephrol. 20, 473\u2013485 (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"19346_CR5","doi-asserted-by":"publisher","first-page":"e184852","DOI":"10.1001\/jamanetworkopen.2018.4852","volume":"1","author":"M Tonelli","year":"2018","unstructured":"Tonelli, M. et al. Comparison of the complexity of patients seen by different medical subspecialists in a universal health care system. JAMA Netw. Open. 1, e184852. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.4852 (2018).","journal-title":"JAMA Netw. Open."},{"key":"19346_CR6","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.2169\/internalmedicine.0108-17","volume":"57","author":"Y Iwashita","year":"2018","unstructured":"Iwashita, Y. et al. A survey of drug burden in patients undergoing maintenance Hemodialysis in Japan. Intern. Med. 57, 2937\u20132944 (2018).","journal-title":"Intern. Med."},{"key":"19346_CR7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","volume":"31","author":"GA Block","year":"1998","unstructured":"Block, G. A., Hulbert-Shearon, T. E., Levin, N. W. & Port, F. K. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic Hemodialysis patients: a National study. Am. J. Kidney Dis. 31, 607\u2013617 (1998).","journal-title":"Am. J. Kidney Dis."},{"key":"19346_CR8","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block, G. A. et al. Mineral metabolism, mortality, and morbidity in maintenance Hemodialysis. J. Am. Soc. Nephrol. 15, 2208\u20132218 (2004).","journal-title":"J. Am. Soc. Nephrol."},{"key":"19346_CR9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/1744-9987.12030","volume":"17","author":"M Taniguchi","year":"2013","unstructured":"Taniguchi, M. et al. Serum phosphate and calcium should be primarily and consistently controlled in prevalent Hemodialysis patients. Ther. Apher Dial. 17, 221\u2013228 (2013).","journal-title":"Ther. Apher Dial"},{"key":"19346_CR10","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.2169\/internalmedicine.2676-19","volume":"58","author":"M Ohya","year":"2019","unstructured":"Ohya, M. et al. An analysis of medication adherence and patient preference in long-term stable maintenance Hemodialysis patients in Japan. Intern. Med. 58, 2595\u20132603 (2019).","journal-title":"Intern. Med."},{"key":"19346_CR11","unstructured":"Guideline for preparing cost-effectiveness evaluation to the Central Social Insurance Medical Council. Core to Evidence-Based Health Policy (C2H), National Institute of Public Health, Japan. (2024). https:\/\/c2h.niph.go.jp\/tools\/guideline\/guideline_en_2024.pdf"},{"key":"19346_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jval.2010.10.015","volume":"14","author":"JC Tosh","year":"2011","unstructured":"Tosh, J. C., Longworth, L. J. & George, E. Utility values in National Institute for health and clinical excellence (NICE) technology appraisals. Value Health. 14, 102\u2013109 (2011).","journal-title":"Value Health"},{"key":"19346_CR13","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jval.2020.12.017","volume":"24","author":"LS Matza","year":"2021","unstructured":"Matza, L. S., Stewart, K. D., Lloyd, A. J., Rowen, D. & Brazier, J. E. Vignette-based utilities: usefulness, limitations, and methodological recommendations. Value Health. 24, 812\u2013821 (2021).","journal-title":"Value Health"},{"key":"19346_CR14","doi-asserted-by":"publisher","first-page":"e444","DOI":"10.1002\/edm2.444","volume":"6","author":"S Ahmed","year":"2023","unstructured":"Ahmed, S. et al. Medication adherence and health-related quality of life among people with diabetes in bangladesh: A cross-sectional study. Endocrinol. Diabetes Metab. 6, e444 (2023).","journal-title":"Endocrinol. Diabetes Metab."},{"key":"19346_CR15","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s10198-014-0649-6","volume":"16","author":"LS Matza","year":"2015","unstructured":"Matza, L. S. et al. Health state utilities associated with attributes of treatments for hepatitis C. Eur. J. Health Econ. 16, 1005\u20131018 (2015).","journal-title":"Eur. J. Health Econ."},{"key":"19346_CR16","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s11136-022-03290-0","volume":"32","author":"LS Matza","year":"2023","unstructured":"Matza, L. S., Howell, T. A., Chounta, V. & van de Velde, N. Patient preferences and health state utilities associated with the treatment process of antiretroviral therapy for people living with HIV. Qual. Life Res. 32, 531\u2013541 (2023).","journal-title":"Qual. Life Res."},{"key":"19346_CR17","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1080\/13696998.2023.2176678","volume":"26","author":"HM de Freitas","year":"2023","unstructured":"de Freitas, H. M., Danese, D., Hubig, L., Lloyd, A. & Lombardelli, S. Estimating health state utilities in primary hyperoxaluria type 1: a valuation study. J. Med. Econ. 26, 386\u2013393 (2023).","journal-title":"J. Med. Econ."},{"key":"19346_CR18","doi-asserted-by":"publisher","first-page":"205435812091442","DOI":"10.1177\/2054358120914426","volume":"7","author":"RJ Solimano","year":"2020","unstructured":"Solimano, R. J., Lineen, J. & Naimark, D. M. J. Preference for alternate-day versus conventional in-center dialysis: a health utility elicitation. Can. J. Kidney Health Dis. 7, 2054358120914426. https:\/\/doi.org\/10.1177\/2054358120914426 (2020).","journal-title":"Can. J. Kidney Health Dis."},{"key":"19346_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12955-015-0266-9","volume":"13","author":"EW Davies","year":"2015","unstructured":"Davies, E. W. et al. Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring Dialysis. Health Qual. Life Outcomes. 13, 90. https:\/\/doi.org\/10.1186\/s12955-015-0266-9 (2015).","journal-title":"Health Qual. Life Outcomes"},{"key":"19346_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s41669-021-00302-6","volume":"6","author":"SH Lo","year":"2022","unstructured":"Lo, S. H., Lloyd, A., Elkhalifa, S., Sisic, Z. & van Nooten, F. E. Time trade-off utilities for hereditary angioedema health and caregiver States. Pharmacoecon Open. 6, 231\u2013239 (2022).","journal-title":"Pharmacoecon Open."},{"key":"19346_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1477-7525-6-84","volume":"6","author":"B Nafees","year":"2008","unstructured":"Nafees, B., Stafford, M., Gavriel, S., Bhalla, S. & Watkins, J. Health state utilities for Non small cell lung cancer. Health Qual. Life Outcomes. 6, 84. https:\/\/doi.org\/10.1186\/1477-7525-6-84 (2008).","journal-title":"Health Qual. Life Outcomes"},{"key":"19346_CR22","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1111\/ajco.12477","volume":"13","author":"B Nafees","year":"2017","unstructured":"Nafees, B., Lloyd, A. J., Dewilde, S., Rajan, N. & Lorenzo, M. Health state utilities in non-small cell lung cancer: an international study. Asia Pac. J. Clin. Oncol. 13, e195\u2013e203. https:\/\/doi.org\/10.1111\/ajco.12477 (2017).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"19346_CR23","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1080\/13696998.2023.2197811","volume":"26","author":"T Ishida","year":"2023","unstructured":"Ishida, T., Nakakoji, M., Murata, T., Matsuyama, F. & Iida, S. Evaluating process utilities for the treatment burden of chemotherapy in multiple myeloma in japan: a time trade-off valuation study. J. Med. Econ. 26, 565\u2013573 (2023).","journal-title":"J. Med. Econ."},{"key":"19346_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jval.2018.05.010","volume":"22","author":"E Stolk","year":"2019","unstructured":"Stolk, E., Ludwig, K., Rand, K., van Hout, B. & Ramos-Go\u00f1i, J. M. Overview, update, and lessons learned from the international EQ-5D-5L valuation work: version 2 of the EQ-5D-5L valuation protocol. Value Health. 22, 23\u201330 (2019).","journal-title":"Value Health"},{"key":"19346_CR25","unstructured":"e-Stat & The Portal Site of Official Statistics of Japan. 2020 Population Census, Table number 2\u2009\u2013\u20091. (2021). https:\/\/www.e-stat.go.jp\/en\/stat-search\/files?stat_infid=000032142404"},{"key":"19346_CR26","unstructured":"e-Stat & The Portal Site of Official Statistics of Japan. Population Census, Table number 1\u20131., Table number 1\u20131. (2020). https:\/\/www.e-stat.go.jp\/en\/stat-search\/files?stat_infid=000032142402 (2021)."},{"key":"19346_CR27","unstructured":"e-Stat & The Portal Site of Official Statistics of Japan. 2020 Population Census, Table number 7\u2009\u2013\u20092. (2021). https:\/\/www.e-stat.go.jp\/en\/stat-search\/files?stat_infid=000032142489"},{"key":"19346_CR28","unstructured":"e-Stat & The Portal Site of Official Statistics of Japan. Employment Status Survey, Table number 2\u2009\u2013\u20091., Table number 2\u2009\u2013\u20091. (2022). https:\/\/www.e-stat.go.jp\/en\/stat-search\/files?stat_infid=000040077243 (2023)."},{"key":"19346_CR29","unstructured":"e-Stat & The Portal Site of Official Statistics of Japan. Employment Status Survey, Table number 11\u2009\u2013\u20091., Table number 11\u2009\u2013\u20091. (2022). https:\/\/www.e-stat.go.jp\/en\/stat-search\/files?stat_infid=000040077266 (2023)."},{"key":"19346_CR30","unstructured":"e-Stat & The Portal Site of Official Statistics of Japan. Employment Status Survey, Table number 116., Table number 116. (2022). https:\/\/www.e-stat.go.jp\/en\/stat-search\/files?stat_infid=000040077387 (2023)."},{"key":"19346_CR31","unstructured":"Ministry of Health, Labour and Welfare. Summary report of comprehensive survey of living conditions 2022. Table 7 in statistics Table (2023). https:\/\/www.mhlw.go.jp\/english\/database\/db-hss\/dl\/report_gaikyo_2022.pdf"},{"key":"19346_CR32","unstructured":"Ministry of Health, Labour and Welfare. Summary report of comprehensive survey of living conditions 2022. Table 10 in statistics Table (2023). https:\/\/www.mhlw.go.jp\/english\/database\/db-hss\/dl\/report_gaikyo_2022.pdf"},{"key":"19346_CR33","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.jval.2015.07.004","volume":"18","author":"C Mukuria","year":"2015","unstructured":"Mukuria, C., Rowen, D., Brazier, J. E., Young, T. A. & Nafees, B. Deriving a preference-based measure for myelofibrosis from the EORTC QLQ-C30 and the MF-SAF. Value Health. 18, 846\u2013855 (2015).","journal-title":"Value Health"},{"key":"19346_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.archger.2018.06.006","volume":"78","author":"U Shimizu","year":"2018","unstructured":"Shimizu, U., Aoki, H., Sakagami, M. & Akazawa, K. Walking ability, anxiety and depression, significantly decrease EuroQol 5-Dimension 5-Level scores in older Hemodialysis patients in Japan. Arch. Gerontol. Geriatr. 78, 96\u2013100 (2018).","journal-title":"Arch. Gerontol. Geriatr."},{"key":"19346_CR35","doi-asserted-by":"publisher","first-page":"e0256421","DOI":"10.1371\/journal.pone.0256421","volume":"16","author":"K Tsuruya","year":"2021","unstructured":"Tsuruya, K., Arima, H., Iseki, K., Hirakata, H. & Kyushu Dialysis-Related Amyloidosis Study Group. Association of dialysis-related amyloidosis with lower quality of life in patients undergoing Hemodialysis for more than 10 years: the Kyushu Dialysis-Related amyloidosis study. PLoS One. 16, e0256421. https:\/\/doi.org\/10.1371\/journal.pone.0256421 (2021).","journal-title":"PLoS One"},{"key":"19346_CR36","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2147\/CEOR.S212911","volume":"11","author":"T Takura","year":"2019","unstructured":"Takura, T. et al. Health economic evaluation of peritoneal Dialysis based on cost-effectiveness in japan: a preliminary study. Clinicoecon Outcomes Res. 11, 579\u2013590 (2019).","journal-title":"Clinicoecon Outcomes Res."},{"key":"19346_CR37","unstructured":"EUROQOL Group. EUROQOL instruments. (2025). https:\/\/euroqol.org\/information-and-support\/euroqol-instruments\/eq-5d-3l\/"},{"key":"19346_CR38","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12882-015-0110-9","volume":"16","author":"C Cabrera","year":"2015","unstructured":"Cabrera, C. et al. A retrospective, longitudinal study estimating the association between interdialytic weight gain and cardiovascular events and death in Hemodialysis patients. BMC Nephrol. 16, 113 (2015).","journal-title":"BMC Nephrol."},{"key":"19346_CR39","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/nep.12891","volume":"22","author":"F Koiwa","year":"2017","unstructured":"Koiwa, F., Yokoyama, K., Fukagawa, M., Terao, A. & Akizawa, T. Efficacy and safety of sucroferric oxyhydroxide compared with Sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: a randomized, open-label, multicentre, 12-week phase III study. Nephrol. (Carlton). 22, 293\u2013300 (2017).","journal-title":"Nephrol. (Carlton)"},{"key":"19346_CR40","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1681\/ASN.2018080832","volume":"30","author":"GA Block","year":"2019","unstructured":"Block, G. A., Rosenbaum, D. P., Yan, A. & Chertow, G. M. Efficacy and safety of Tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: a randomized phase 3 trial. J. Am. Soc. Nephrol. 30, 641\u2013652 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"19346_CR41","doi-asserted-by":"publisher","first-page":"19100","DOI":"10.1038\/s41598-023-45080-9","volume":"13","author":"F Koiwa","year":"2023","unstructured":"Koiwa, F. et al. Long-term safety and decrease of pill burden by Tenapanor therapy: a phase 3 open-label study in Hemodialysis patients with hyperphosphatemia. Sci. Rep. 13, 19100. https:\/\/doi.org\/10.1038\/s41598-023-45080-9 (2023).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19346-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19346-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19346-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:39:20Z","timestamp":1760017160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19346-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["19346"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-19346-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was entirely funded by Kyowa Kirin Co., Ltd.Masatomo Taniguchi received honoraria from Kyowa Kirin Co., Ltd., Bayer Yakuhin Ltd., Mitsubishi Tanabe Pharma Corporation, Kissey Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Torii Pharmaceutical Co., Ltd., and Daiichi Sankyo Company Ltd. Suguru Yamamoto received honoraria and consulting fees from Sanwa Kagaku Kenkyusho Co., Ltd.; honoraria from Kyowa Kirin Co., Ltd., Kissei Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., and Torii Pharmaceutical Co., Ltd.; and research funding from Toray Medical Co., Ltd. and Kaneka Medix Co., Ltd. Ataru Igarashi received honoraria from Kyowa Kirin Co., Ltd., Bayer Yakuhin Ltd., Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co., Ltd., Astra Zeneca K.K., Toray Medical Co., Ltd., Novo Nordisk Pharma Ltd. and Eli Lilly Japan K.K. Hiroo Shimoda, Shin Tokunaga, and Shinji Asada are employees of Kyowa Kirin Co., Ltd.Keigo Hanada, Naoki Tashiro, and Tatsunori Murata are employees of CRECON Medical Assessment Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35315"}}